α-Subunit selective modulators of GABA_A receptor function as CNS therapeutics

Bibliography

• BARNES EM Jr: Assembly and intracellular trafficking of GABAA receptors. Int. Rev. Neurobiol (2001) 48:1–29.
   PubMedGoogle Scholar
• BARNARD EA: The molecular architecture of GABAA receptors. Handbook Exp. Pharinacol (2001) 150:79–99.
   Google Scholar
• SIEGHART W, FUCHS K, TRETTER V et al.: Structure and subunit composition of GABAA receptors. Neurochein. Int. (1999) 34:379–385.
   PubMedGoogle Scholar
• MCKERNAN RIVI, WHITING PJ: Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci. (1996) 19(4):139–143.
   Google Scholar
• MOHLER H: Functions of GABAA receptors: pharmacology and pathophysiology. Handbook Exp. Pharinacol (2001) 150:101–116.
   Google Scholar
• SMITH TAD: Type A y-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment. Br. J. Bionted. Sci. (2001) 58(2):111–121.
   PubMedGoogle Scholar
• MOHLER H, CRESTANI F, RUDOLPH U: GABAA-receptor subtypes: a new pharmacology. Curr. Opin. Pharinacol (2001) 1(1):22–25.
   PubMedGoogle Scholar
• KORPI ER, GRUNDER G, LUDDENS H: Drug interactions at GABAA receptors. Frog. Neurobiol (2002) 67(2):113–159.
   Google Scholar
• WINGROVE PB, SAFO P, WHEAT L, THOMPSON SA, WAFFORD KA, WHITING PJ: Mechanism of a-subunit selectivity of benzodiazepine pharmacology at y-aminobutyric acid type A receptors. Eur. Pharinacol (2002) 437(1-2):31–39.
   PubMedGoogle Scholar
• RUDOLPH U, CRESTANI F, MOHLER H: GABAA receptor subtypes: dissecting their pharmacological functions. Trends Pharinacol Sci. (2001) 22(4E188–194.
   Google Scholar
• ••Review of subunit pharmacology andassociated physiology.
   Google Scholar
• MOHLER H, FRITSCHY JM, RUDOLPH U: A new benzodiazepine pharmacology. J. Pharinacol Exp. Titer: (2002) 300(1):2–8.
   PubMed Web of Science ®Google Scholar
• LOW K, CRESTANI F, KEIST R et al.: Molecular and neuronal substrate for the selective attenuation of anxiety. Science (2000) 290:131–134.
   PubMed Web of Science ®Google Scholar
• RUDOLPH U, CRESTANI F, BENKE D et al.: Benzodiazepine actions mediated by specific y-aminobutyric acidA receptor subtypes. Nature (1999) 401(6755):796–800.
   PubMed Web of Science ®Google Scholar
• MCKERNAN RIVI, ROSAHL TW, REYNOLDS DS et al.: Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor al subunit. Nature Neurosci. (2000) 3(6):587–592.
   PubMedGoogle Scholar
• •Links the ce1 subunit with sedation.
   Google Scholar
• CRESTANI F, LOW K, KEIST R, MANDELLI M-J, MOHLER H, RUDOLPH U: Molecular targets for the myorelaxant action of diazepam. Ma Pharinacol (2001) 59(3):442–445.
   PubMedGoogle Scholar
• CRESTANI F, MARTIN JR, MOHLER H, RUDOLPH U: Mechanism of action of the hypnotic zolpidem in vivo. Br. J. Pharinacol (2000) 131(7):1251–1254.
   PubMedGoogle Scholar
• DOBLE A: New insights into the mechanismof action of hypnotics. I Psychopharinacol (1999) 13(4, Suppl. 1):11–20.
   Google Scholar
• PRITCHETT DB, LUDDENS H, SEE BURG PH: Type I and type II GABAA-benzodiazepine receptors produced in transfected cells. Science (1989) 245:1389–1392.
   PubMed Web of Science ®Google Scholar
• BARNARD EA, SKOLNICK P, OLSEN RW et at. International Union of Pharmacology. XV. Subtypes of y-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharinacol. Rev. (1998) 50(2):291–313.
   Google Scholar
• GUNNERSEN D, KAUFMAN CM, SKOLNICK P: Pharmacological properties of recombinant ''diazepam-insensitive'' GABAA receptors. Neuropharinacology (1996) 35(9/10):1307–1314.
   Google Scholar
• PRADO DE CARVALHO L, GRECKSCH G, CHAPOUTHIER G, ROSSIER J: Amdogenic and non-amdogenic benzodiazepine antagonists. Nature (1983) 301(5895):64–66.
   PubMedGoogle Scholar
• BRAESTRUP C, SCHMIECHEN R, NEEF G, NIELSEN M, PETERSEN EN: Interaction of convulsive ligands with benzodiazepine receptors. Science (1982) 216(4551):1241–1243.
   PubMedGoogle Scholar
• HARRIS CM, LAL H: Central nervous system effects of the imidazodiazepine Ro 15-4513. Drug Dev. Res. (1988) 13(4):187–203.
   Google Scholar
• COLLINS I, DAVEY WB, ROWLEY M et al.: N-(Indo1-3-ylglyoxylyflpiperidines: high affinity agonists of human GABAA receptors containing the al subunit. Bioorg. Med. Chem. Lett. (2000) 10(12):1381–1384.
   PubMedGoogle Scholar
• MACDONALD A, MICHAELIS AF, SENKOWSKI BZ: Diazepam. Anal. Profiles Drug Subst. (1972) 1:79–99.
   Google Scholar
• HUNKELER W: Benzodiazepines, the story of the antagonist flumazenil and of the partial agonist bretazenil. Chimia (1993) 47(5):141–147.
   Google Scholar
• SANGER DJ, DEPOORTERE H: The pharmacology and mechanism of action of zolpidem. CNS Drug Reviews (1998) 4(4):323–340.
   PubMedGoogle Scholar
• DOOLEY M, PLOSKER GL: Zaleplon: a review of its use in the treatment of insomnia. Drugs (2000) 60(2):413–445.
   PubMed Web of Science ®Google Scholar
• HAJAK G: A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience. Drug Safety (1999) 21(6):457–469.
   PubMed Web of Science ®Google Scholar
• PRIBILLA I, NEUHAUS R, HUBA R, et al.: Abecarnil is a full agonist at some, and a partial agonist at other recombinant GABAAreceptor subtypes. Psychophannacol Ser. (1993) 11:50–61.
   Google Scholar
• SERRA M, GHIANI CA, MOTZO C, BIGGIO G: Pharmacological evidence for full agonist activity of abecarnil at certain GABAA receptors. Psychopharinacol Ser: (1993) 11:62–78.
   PubMedGoogle Scholar
• STEPHENS DN, TURSKI L, JONES GH, STEPPUHN KG, SCHNEIDER HH: Abecarnil: a novel anxiolytic with mixed full agonist/patial gonist properties in animal models of anxiety and sedation. Psychopharinacol Ser. (1993) 11:79–95.
   PubMedGoogle Scholar
• LOSCHER W: Abecarnil shows reduced tolerance development and dependence potential in comparison to diazepam: animal studies. Psychophannacol. Ser. (1993) 11:96–112.
   PubMedGoogle Scholar
• SANNERUD CA, ATOR NA, GRIFFITHS RR: Behavioural pharmacology of abecarnil in baboons: reduced dependence and abuse potential. Psychopharinacol Ser: (1993) 11:113–120.
   PubMedGoogle Scholar
• EMMETT-OGLESBY MW, LYTLE DA, ENGLISH SA: Abecarnil used to treat benzodiazepine withdrawal. Psychophannacol Ser. (1993) 11:121–131.
   PubMedGoogle Scholar
• DUKA T, KRAUSE W, DOROW R, ROHLOFF A, OTT H, VOET B. Abecarnil: a new I3-carotene anxiolytic preliminary clinical pharmacology. Psychopharinacol Ser. (1993) 11:132–147.
   PubMedGoogle Scholar
• BARKER JL, MATHERS DA: GABA receptors and the depressant action of pentobarbital. Trends NeuroSci. (1981) 4(1):10–13.
   Google Scholar
• Al J, WANG X, NIELSEN M: Honokiol and magnolol selectively interact with GABAA receptor subtypes in vitro. Pharmacology(2001) 63(1):34–41.
   PubMedGoogle Scholar
• GRIEBEL G, PERRAULT G, SIMIAND J et al.: SL651498: an anxioselective compound with functional selectivity for a2-and a3-containing y-aminobutyric acidA (GABAA) receptors. I Pharmacol Exp. The]: (2001) 298(2):753–768.
   PubMedGoogle Scholar
• COLLINS I, MOYES C, DAVEY WB et al.: 3-Heteroary1-2-pyridones: benzodiazepine site ligands with functional selectivity for a2/a3-subtypes of human GABAA receptor-ion channels.' Med. Chem. (2002) 45:1887–1900.
   Google Scholar
• ADKINS CE, PILLAI GV, KERBYJ et al: a4338 GABAA receptors characterized by fluorescence resonance energy transfer-derived measurements of membrane potential." Biol. Chem. (2001) 276(42):38934–38939.
   Google Scholar
• SMITH SS, GONG QH, HSU F-C, MARKOWITZ RS, FFRENCH-MULLEN JMH, LI X: GABAA receptor a4 subunit expression prevents withdrawal properties of an endogenous steroid. Nature (1998) 392:926–930.
   PubMed Web of Science ®Google Scholar
• COLE SO: Effects of benzodiazepines on acquisition and performance: a critical assessment. Neurosci. Biobehav. Rev. (1986) 10:265–272.
   PubMedGoogle Scholar
• GHONEIM MM, MEWALDT SP: Benzodiazepines and human memory: a review. Anesthesiology (1990) 72:926–938.
   PubMed Web of Science ®Google Scholar
• MCNAMARA RK, SKELTON RW: Benzodiazepines receptor antagonists flumazenil and CGS 8216 and inverse agonist I3-CCM enhance spatial learning in the rat: dissociation from amdogenic actions. Psychobiology (1993) 21:101–108.
   Google Scholar
• MACLEOD AM, DAWSON GR, PILLAI G et al: Discovery of GABAA a5 subtype selective inverse agonists as cognition enhancers. Abstr. Pap. Am. Chem. Sot: 22P' ACS National Meeting, San Diego, USA (2001) MEDI187.
   Google Scholar
• HUANG Q, HEX, MA C et al: Pharmacophore/receptor models for GABAA/ BzR subtypes (a133y2, a513372, and a613372) via a comprehensive ligand-mapping appmach.j Med. Chem. (2000) 43:71–95.
   PubMedGoogle Scholar
• YU S, MA C, HEX et al.: Studies in the search for a5 subtype selective agonists for GABAA/BzR sites. Med. Chem. Res. (1999) 9(2):71–88.
   Google Scholar
• CASULA MA, BROMIDGE FA, PILLAI GV et al: Identification of amino acid residues responsible for the a5 subunit binding selectivity of L-655,708, a benzodiazepine binding site ligand at the GABAA receptor. Neurochem. (2001) 77(2):445–451.
   PubMedGoogle Scholar
• STRAKHOVA MI, HARVEY SC, COOK CM, COOK JM, SKOLNICK P: A single amino acid residue on the a5 subunit (I1e2 15) is essential for ligand selectivity at a5133y2 y-aminobutyric acidA receptors. MM. Pharmacol (2000) 58:1434–1440.
   PubMedGoogle Scholar
• SKOLNICK P, HU RJ, COOK CM et al: [3H]RY 80: a high affinity, selective ligand for g-aminobutyric acidA receptors containing alpha-5 subunits. j. Pharmacol Exp. Ther (1997) 283(2):488–493.
   PubMedGoogle Scholar
• BAILEY DJ, TETZLAFF JE, COOK JM, HE X, HELMSTETTER FJ: Effects of hippocampal injections of a novel ligand selective for the a5132y2 subunits of the GABA/benzodiazepine receptor on Pavlovian conditioning. Neurobiol Learning Memory (2002):78(1):1–10.
   PubMedGoogle Scholar
• CHAMBERS MS, ATACK JR, BROMIDGE FA et al.: 6,7-Dihydro-2-benzothiophen-4(51-4-ones: a novel class of GABA-A a5 receptor inverse agonists. Med. Chem. (2002) 45:1176–1179.
   Google Scholar
• JACKEL C, KLEINZ R, MAKELA R et al.: The main determinant of furosemide inhibition on GABAA receptors is located close to the first transmembrane domain. Eur. Pharmacol (1998) 357:251–256.
   PubMedGoogle Scholar
• LUDDENS H, LANG H-J, KORPI ER: Structure-activity relationship of furosemide-derived compounds as antagonists of cerebellum-specific GABAA receptors. Ear: Pharmacol (1998) 344:269–277.
   PubMedGoogle Scholar
• FISHER JL: Amiloride inhibition of y-aminobutyric acidA receptors depends upon the a subunit subtype. MM. Pharmacol (2002) 61(6):1322–1328.
   PubMedGoogle Scholar
• DEL RIO JC, ARAUJO F, RAMOS B, RUANO D, VITORICA J: Prevalence between different a subunits performing the benzodiazepine binding sites in native heterologous GABAA receptors containing the a2 subunit. I Neurochem. (2001) 79(1):183–191.
   PubMedGoogle Scholar
• TANAY V-M, GREENSHAW AJ, BAKER GB, BATES ON AN: Common effects of chronically administered antipanic drugs on brainstem GABAA receptor subunit gene expression. MM. Psychiatry (2001) 6(4):404–412.
   Google Scholar
• SMITH AJ, ALDER L, SILK J et al.: Effect of a subunit on allosteric modulation of ion channel function in stably expressed human recombinant y-aminobutyric acidA receptors determined using 36C1 ion flux. MM. Pharmacol (2001) 59(5):1108–1118.
   PubMedGoogle Scholar
• MEADOWS HJ, KUMAR CS, PRITCHETT DB, BLACKBURN TP, BENHAM CD: SB-205384: a GABAA receptor modulator with novel mechanism of action that shows subunit selectivity. Br. Pharmacol (1998) 123(6):1253–1259.
   PubMedGoogle Scholar